

## Atherosclerosis and its Impact on Cardiovascular Health

Jing Li\*

Department of Cardiovascular Diseases, Shanghai Jiao Tong University, Shanghai, China

### Abstract

Atherosclerosis is a condition characterized by the hardening and narrowing of the highways, which can lead to health complications such as heart attacks, strokes, and peripheral artery disease. The accumulation of shrine within blood vessels can make them fragile and prone to rupture, leading to the formation of blood clots that obstruct blood flow. This condition can also cause angina and transient ischemic attacks. Managing atherosclerosis involves a multifaceted approach, including lifestyle changes, medications, and invasive procedures. Ongoing research is exploring new treatment options, including anti-inflammatory therapies such as methotrexate and IL-1 $\beta$  inhibition. Early detection and prevention are crucial for maintaining optimal cardiovascular health.

**Keywords:** Atherosclerosis; Heart attacks; Cardiovascular conditions; Transient ischemic attacks; Cerebral embolism; Erectile dysfunction

### Description

Atherosclerosis refers to the hardening and narrowing of highways, which can affect in colorful health complications. It's also known as atherosclerotic cardiovascular complaint or arteriosclerosis and is a leading cause of cardiovascular conditions similar as heart attacks, strokes, and supplemental vascular complaint. The accumulation of shrine within blood vessels can make them fragile and prone to rupture. This can lead to the conformation of blood clots that obstruct the inflow of blood to other corridor of the body. When a clot blocks a blood vessel in the brain, it causes a stroke. Ischemic strokes, caused by blood clots, can do due to the narrowing of blood vessels in the brain caused by atherosclerosis or other patches that block the blood inflow. Cerebral embolism occurs when a clot or other flyspeck, known as an embolus, travels through the bloodstream and lodges in an roadway of the brain, blocking blood inflow [1]. Embolisms can be caused by shrine or a piece of clot that breaks off from an atherosclerotic shrine. Still, this condition is generally observed in individualities with atrial fibrillation (Figure 1).

### Transient ischemic attacks (TIA)

Transient Ischemic Attacks (TIA) generally last for a many twinkles to an hour, although in rare cases, symptoms may persist for over to 24 hours. TIA shares analogous signs and symptoms with stroke, similar as the unforeseen onset of weakness, impassiveness, or palsy in the face, arm, or leg, generally affecting one side of the body. Other symptoms may include vocalized speech or difficulty understanding others, blindness in one or both eyes, double vision, and loss of balance or collaboration, intermittent TIAs can do, and the symptoms may be analogous or different depending on the specific area of the brain involved [2].

### Angina

Angina refers to casket pain or discomfort caused by shy oxygen force to the heart muscle through the blood. It manifests as pressure or squeezing sensations in the casket and can also be felt in the shoulders, arms, neck, jaw, or back. Angina pain may act indigestion. Angina isn't a complaint itself but rather a symptom of an beginning heart condition, generally Coronary Heart complaint (CHD). There are colorful types of angina, including Prinzmetal's angina, microvascular angina, stable angina, variant angina, and unstable angina. These conditions arise when one or further coronary highways come narrowed, leading to




Figure 1: Complications of atherosclerosis.

reduced blood inflow, also known as ischemia. Angina can also be a symptom of Coronary Microvascular complaint (MVD) [3].

### Heart attack

A heart attack occurs when the inflow of blood to the heart is blocked by the accumulation of fat, cholesterol and other substances, which form a shrine in the highways of the heart (coronary highways). Occasionally, a shrine can rupture and form a clot that obstructs the blood inflow. The interrupted blood inflow can destroy part of the heart muscle. Myocardial contravention also called as heart attack.

\*Corresponding author: Jing Li, Department of Cardiovascular Diseases, Shanghai Jiao Tong University, Shanghai, China, E-mail: jing@jiaotong.edu.cn

Received: 26-Apr-2023, Manuscript No. asoa-23-99850; Editor assigned: 28-Apr-2023, PreQC No. asoa-23-99850(PQ); Reviewed: 12-May-2023, QC No. asoa-23-99850; Revised: 18-May-2023, Manuscript No. asoa-23-99850(R); Published: 25-May-2023, DOI: 10.4172/aso.1000203

Citation: Li J (2023) Atherosclerosis and its Impact on Cardiovascular Health. Atheroscler Open Access 8: 203.

Copyright: © 2023 Li J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## Kidney

In cases of atherosclerosis, the accumulation of plaque causes the arteries to harden, leading to reduced blood flow to the organs (stenosis). This can affect in the development of chronic kidney disease (CKD) and potentially progress to End-Stage renal disease (ESRD), particularly as individuals age. Arrhythmogenic Right Ventricular Dysplasia (ARVD) can contribute to the development of CKD in the environment of atherosclerosis.

## Male organ

Erectile Dysfunction (ED) is frequently associated with blockages in the arteries. The condition is primarily related to reduced blood flow. Plaque buildup in the arteries can stymie proper blood flow, potentially leading to ED [4].

## Peripheral artery disease

Peripheral Artery Disease (also known as peripheral arterial disease) is a common circulatory condition characterized by the narrowing of arteries, resulting in reduced blood flow to the limbs. In this condition, generally associated with atherosclerosis, the legs, and occasionally the arms, don't admit an acceptable blood flow. Symptoms may include leg pain while walking. Treatment for peripheral artery disease involves regular exercise, a healthy diet, and cessation of tobacco use, which can help improve blood flow and manage the condition [5].

## Anti-inflammatory treatment

Other intriguing implicit treatments include both unspecific and specific approaches. In RA, treatment with methotrexate weekly is routinely used, with salutary results on cases. A recent meta-analysis indicates that the threat of CVD is reduced in cases with RA treated with methotrexate [5]. Preclinical studies in which methotrexate decreases atherogenesis add support to methotrexate as a possible anti-inflammatory treatment in CVD [6]. In the Cardiovascular Inflammation Reduction Trial (CIRT) low-dose methotrexate (target dose 20 mg/week) is tested for reduction of major CVD events among post-myocardial infarction cases with diabetes or metabolic syndrome [7]. There are numerous implicit treatments that show promise in addressing cardiovascular disease (CVD) through both nonspecific and specific approaches. In the treatment of rheumatoid arthritis (RA), methotrexate is generally used on a daily basis and has demonstrated salutary results for cases. A recent meta-analysis has indeed suggested that RA cases treated with methotrexate may witness a reduced threat of CVD [8]. Likewise, preclinical studies have shown that methotrexate can reduce the development of atherosclerosis, further supporting its potential as an anti-inflammatory treatment for CVD [9]. The Cardiovascular Inflammation Reduction Trial (CIRT) is presently probing the use of low-dose methotrexate (with a target dose of 20 mg/week) for reducing major CVD events in post-myocardial infarction cases with diabetes or metabolic syndrome [10]. This trial aims to estimate the effectiveness of methotrexate as a treatment option in reducing CVD-related complications. These findings punctuate the potential of methotrexate as a treatment for CVD and the ongoing exploration seeks to explore its benefits in diverse patient populations. By targeting inflammation, methotrexate may offer a new approach to mitigating CVD risk and addressing issues for individuals at high risk of CVD events. Originally, in the treatment of rheumatoid arthritis (RA), treatments targeting specific molecules like tumor necrosis factor (TNF) inhibitors have shown success. Also, new biologics that inhibit other cytokines are being explored. Still, there

are differing opinions regarding the cardiovascular benefits of birth treatments, including anti-TNF agents. Nevertheless, a recent study has provided substantiation suggesting a potential drop in cardiovascular disease (CVD) among RA cases, advancing support to the notion of cardiovascular benefits associated with these treatments [11,12]. The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) is presently probing the potential of inhibiting interleukin-1 $\beta$  (IL-1 $\beta$ ) to reduce the threat of myocardial infarction (MI), stroke, and cardiovascular death in stable coronary artery disease cases with high CVD risk due to persistently elevated levels of C-reactive protein (CRP) ( $\geq 2$  mg/L) [105,110]. This study aims to estimate whether IL-1 $\beta$  inhibition can give cardiovascular benefits in this patient population. In addition to birth treatments, other interesting treatment approaches include targeting pro-inflammatory lipids similar to platelet-activating factor (PAF) [13,14]. Our recent exploration has demonstrated that Annexin A5, an anti-thrombotic membrane protein, exhibits anti-inflammatory properties and inhibits the development of atherosclerosis, while also perfecting endothelial function in a mouse model. This suggests that Annexin A5 could represent another potential treatment [15,16]. Also, the inhibition of phospholipases (PLs), including lipoprotein-associated phospholipase A2 (Lp-PLA2), is of interest. Clinical studies probing the inhibition of Lp-PLA2 activity using darapladib in cases following an acute coronary syndrome are presently underway [17-21].

These emerging remedial strategies, whether through birth interventions or the targeting of specific pro-inflammatory molecules, offer potential avenues for addressing cardiovascular issues. Ongoing exploration and clinical trials will help to further interpret the effectiveness and safety of these treatments in the environment of cardiovascular health.

## Discussion

Understanding the impact of atherosclerosis on cardiovascular health is pivotal for managing and preventing associated complications. Atherosclerosis refers to the buildup of plaque in the arteries, causing them to narrow and harden over time [22]. This condition can have significant consequences for the heart and blood vessels, leading to various cardiovascular problems. One of the primary impacts of atherosclerosis is the reduced blood flow to vital organs and tissues. As plaque accumulates in the arteries, it restricts the passage of oxygen-rich blood to the heart, brain, muscles, and other organs [23]. This diminished blood flow can lead to serious complications, including heart attacks, strokes, and chronic kidney disease. In the heart, atherosclerosis can lead to coronary artery disease (CAD), which is characterized by the narrowing of the arteries supplying blood to the heart muscle. When the blood flow is significantly reduced, it can cause angina (chest pain) or even a heart attack if the blood flow is fully blocked. Atherosclerosis-related CAD is a leading cause of heart disease and remains a major health concern worldwide [24]. Atherosclerosis also poses a threat to brain health. When the arteries supplying blood to the brain become blocked or narrowed due to plaque buildup, it can lead to a stroke. Strokes occur when the brain is deprived of oxygen and nutrients, leading to damage in the affected area. This can result in various neurological deficits, including paralysis, speech difficulties, and cognitive impairments. Also, atherosclerosis can affect peripheral arteries, primarily in the legs. Peripheral artery disease (PAD) occurs when the arteries in the legs become narrowed or blocked, reducing blood flow to the lower extremities [25]. This can cause leg pain, cramping, and difficulty walking, limiting mobility and impacting quality of life. Managing atherosclerosis and

its impact on cardiovascular health involves a multifaceted approach. Life variations similar as espousing a healthy diet, engaging in regular physical exertion, quitting smoking, and managing stress can help reduce the progression of atherosclerosis. Specifics, including cholesterol-lowering medicines and blood thinners, may be specified to manage threat factors and help complications. In some cases, invasive procedures like angioplasty, stenting, or bypass surgery may be necessary to restore blood inflow to affected highways. Early discovery, forestallment, and visionary operation of atherosclerosis are pivotal to maintain optimal cardiovascular health. By understanding the impact of this condition and enforcing applicable interventions, individualities can reduce the threat of heart attacks, strokes, and other cardiovascular complications associated with atherosclerosis.

## Conclusion

In conclusion, the progression of atherosclerosis can be braked down or halted through colorful interventions. Aggressive treatment options similar as life changes, drug, angiography and stenting, bypass surgery, and fibrinolytic remedy can help manage the condition. With these approaches, it's possible to not only help farther atherosclerosis but also potentially reduce the size of being pillars. By enforcing a combination of drug and life variations, individualities can take visionary way to manage atherosclerosis and ameliorate their overall cardiovascular health.

## Acknowledgement

Not applicable

## Conflict of Interest

Author declares no conflict of interest.

## References

- Gimbrone MA Jr, Topper JN, Nagel T, Anderson KR, Garcia-Cardena G (2000) Endothelial dysfunction, hemodynamic forces, and atherogenesis. *Ann N Y Acad Sci* 902:230-239.
- Campbell KA, Lipinski MJ, Doran AC, Skafien MD, Fuster V, et al. (2012) Lymphocytes and the adventitial immune response in atherosclerosis. *Circ Res* 110:889-900.
- Frostegard J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, et al. (1999) Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. *Atherosclerosis* 145:33-43.
- Libby P, Ridker PM, Hansson GK (2011) Progress and challenges in translating the biology of atherosclerosis. *Nature* 473:317-325.
- Camejo G, Laguna F, Lopez F, Starosta R (1980) Characterization and properties of a lipoprotein-complexing proteoglycan from human aorta. *Atherosclerosis* 35:307-320.
- Tabas I, Williams KJ, Boren J (2007) Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. *Circulation* 116:1832-1844.
- Frostegard J, Nilsson J, Haegerstrand A, Hamsten A, Wigzell H, et al. (1990) Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. *Proc Natl Acad Sci* 87:904-908.
- Frostegard J, Wu R, Giscombe R, Holm G, Lefvert AK, et al. (1992) Induction of T-cell activation by oxidized low density lipoprotein. *Arterioscler Thromb* 12:461-467.
- Berliner JA, Territo MC, Sevanian A, Ramin S, Kim JA, et al. (1990) Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. *J Clin Invest* 85:1260-1266.
- Elinder LS, Dumitrescu A, Larsson P, Hedin U, Frostegard J, et al. (1997) Expression of phospholipase A2 isoforms in human normal and atherosclerotic arterial wall. *Arterioscler Thromb Vasc Biol* 17:2257-2263.
- Atout R, Karabina SA, Dollet S, Carreras M, Payre C, et al. (2012) Human group X secreted phospholipase A2 induces dendritic cell maturation through lipoprotein-dependent and -independent mechanisms. *Atherosclerosis* 222:367-374.
- Huang YH, Schafer-Elinder L, Wu R, Claesson HE, Frostegard J (1999) Lysophosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism. *Clin Exp Immunol* 116:326-331.
- Goncalves I, Edsfieldt A, Ko NY, Grufman H, Berg K, et al. (2012) Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation. *Arterioscler Thromb Vasc Biol* 32:1505-1512.
- Frostegard J, Huang YH, Ronnelid J, Schafer-Elinder L (1997) Platelet-activating factor and oxidized LDL induce immune activation by a common mechanism. *Arterioscler Thromb Vasc Biol* 17:963-968.
- Watson AD, Leitinger N, Navab M, Faull KF, Horkko S, et al. (1997) Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. *J Biol Chem* 272:13597-13607.
- Greig FH, Kennedy S, Spickett CM (2012) Physiological effects of oxidized phospholipids and their cellular signaling mechanisms in inflammation. *Free Radic Biol Med* 52:266-280.
- Miller YI, Choi SH, Wiesner P, Fang L, Harkewicz R, et al. (2011) Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. *Circ Res* 108:235-248.
- Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, et al. (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet* 364:937-952.
- Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF (2007) Systemic effects of smoking. *Chest* 131:1557-1566.
- Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, et al. (1995) Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers smoking as a cause of oxidative damage. *N Engl J Med* 332:1198-1203.
- Penn A, Snyder CA (1993) Inhalation of sidestream cigarette smoke accelerates development of atherosclerotic plaques. *Circulation* 88:1820-1825.
- Zhu BQ, Sun YP, Sievers RE, Isenberg WM, Glantz SA, et al. (1993) Passive smoking increases experimental atherosclerosis in cholesterol-fed rabbits. *J Am Coll Cardiol* 21:225-232.
- Gairola CG, Drawdy ML, Block AE, Daugherty A (2001) Sidestream cigarette smoke accelerates atherosclerosis in apolipoprotein E-/- mice. *Atherosclerosis* 156:49-55.
- Kunitomo M, Yamaguchi Y, Kagota S, Yoshikawa N, Nakamura K, et al. (2009) Biochemical evidence of atherosclerosis progression mediated by increased oxidative stress in apolipoprotein E-deficient spontaneously hyperlipidemic mice exposed to chronic cigarette smoke. *J Pharmacol Sci* 110:354-361.
- Frostegard J (2005) Atherosclerosis in patients with autoimmune disorders. *Arterioscler Thromb Vasc Biol* 25:1776-1785.